Form 4: Vertex Pharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan

Edward Morrow Atkinson III, an executive at Vertex Pharmaceuticals, sold 1,767 shares of common stock at $480.95 per share on February 25, 2025, according to a Form 4 filing.

Summary

• On February 24, 2025, Edward Morrow Atkinson III, EVP, Chief Technical Operations Officer of Vertex Pharmaceuticals, had 1,656 shares of common stock withheld for taxes at a price of $483.28.
• On February 25, 2025, Atkinson sold 1,767 shares of Vertex Pharmaceuticals common stock at a price of $480.95 per share.
• These transactions were executed under a pre-arranged trading plan (Rule 10b5-1) established on February 22, 2024.
• Following these transactions, Atkinson directly owns 24,484 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often executed under pre-arranged trading plans like Rule 10b5-1 to avoid accusations of insider trading. The filing provides transparency into the transactions of company insiders.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, depending on the overall market perception of the company and the volume of shares traded.

Key Dates